Ulisse Biomed S.p.A. (BIT:UBM)
Italy
· Delayed Price · Currency is EUR 0.7600
-0.0140 (-1.81%)
Jun 27, 2025, 4:33 PM CET
Ulisse Biomed Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Operating Revenue | 0.77 | 0.07 | 0.14 | 0.28 | 0.5 | Upgrade
|
Other Revenue | - | - | - | 0 | 0.11 | Upgrade
|
| 0.77 | 0.07 | 0.14 | 0.28 | 0.61 | Upgrade
| |
Revenue Growth (YoY) | 1059.87% | -52.18% | -50.64% | -53.68% | 5469.84% | Upgrade
|
Cost of Revenue | 1.84 | 1.62 | 1.03 | 0.55 | 0.3 | Upgrade
|
Gross Profit | -1.08 | -1.55 | -0.89 | -0.27 | 0.31 | Upgrade
|
Selling, General & Admin | 2.07 | 0.61 | 0.43 | 0.2 | 0.18 | Upgrade
|
Other Operating Expenses | 0.12 | 0.04 | -0.23 | -0.11 | -0.15 | Upgrade
|
Operating Expenses | 5.12 | 3.3 | 0.52 | 0.34 | 0.08 | Upgrade
|
Operating Income | -6.19 | -4.85 | -1.41 | -0.6 | 0.22 | Upgrade
|
Interest Expense | -0.02 | -0 | -0 | -0 | -0 | Upgrade
|
Interest & Investment Income | - | - | 0 | - | 0 | Upgrade
|
Currency Exchange Gain (Loss) | -0 | -0 | -0 | -0 | -0 | Upgrade
|
Other Non Operating Income (Expenses) | 0.28 | 0.05 | 0.11 | 0 | 0 | Upgrade
|
EBT Excluding Unusual Items | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade
|
Pretax Income | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade
|
Income Tax Expense | - | - | - | - | 0 | Upgrade
|
Net Income | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade
|
Net Income to Common | -5.94 | -4.8 | -1.31 | -0.6 | 0.22 | Upgrade
|
Shares Outstanding (Basic) | 24 | 22 | 8 | 8 | - | Upgrade
|
Shares Outstanding (Diluted) | 24 | 22 | 8 | 8 | - | Upgrade
|
Shares Change (YoY) | 13.50% | 167.46% | 0.01% | - | - | Upgrade
|
EPS (Basic) | -0.24 | -0.22 | -0.16 | -0.07 | - | Upgrade
|
EPS (Diluted) | -0.24 | -0.22 | -0.16 | -0.07 | - | Upgrade
|
Free Cash Flow | -3.56 | -0.97 | -1.05 | -0.39 | -0.6 | Upgrade
|
Free Cash Flow Per Share | -0.14 | -0.04 | -0.13 | -0.05 | - | Upgrade
|
Gross Margin | -140.15% | - | - | -94.64% | 50.57% | Upgrade
|
Operating Margin | -806.30% | -7322.92% | -1020.66% | -215.17% | 37.03% | Upgrade
|
Profit Margin | -773.49% | -7245.12% | -944.65% | -215.23% | 36.64% | Upgrade
|
Free Cash Flow Margin | -463.78% | -1470.94% | -757.58% | -140.77% | -99.52% | Upgrade
|
EBITDA | -3.27 | -2.35 | -1.29 | -0.36 | 0.28 | Upgrade
|
EBITDA Margin | - | - | - | -126.84% | 45.43% | Upgrade
|
D&A For EBITDA | 2.92 | 2.5 | 0.12 | 0.25 | 0.05 | Upgrade
|
EBIT | -6.19 | -4.85 | -1.41 | -0.6 | 0.22 | Upgrade
|
EBIT Margin | - | - | - | -215.17% | 37.03% | Upgrade
|
Effective Tax Rate | - | - | - | - | 1.04% | Upgrade
|
Revenue as Reported | 1.24 | 0.26 | 0.52 | 0.41 | 0.76 | Upgrade
|
Updated Sep 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.